About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

BostonGene Named “AI-based Drug Discovery Solution of the Year” in 2025 AI Breakthrough Awards Program

Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions

BostonGene, a leader in AI-powered solutions for drug discovery and development, has been honored with the “AI-based Drug Discovery Solution of the Year” award in the 8th annual AI Breakthrough Awards program. AI Breakthrough is a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250807891144/en/

BostonGene’s breakthrough AI platform is transforming oncology research and drug development by integrating high throughput tissue analytics with genomic, transcriptomic and clinical data. This multimodal approach creates biological signatures, leading to improved target identification and enhanced patient stratification for clinical trials.

As part of its integrated solution, BostonGene’s novel AI-driven platform combines advanced digital pathology capabilities–such as pixel-level analysis of whole slide images–with molecular and clinical data. The insights that BostonGene’s platform delivers sharpen the precision of predictive biomarker and therapeutic target discovery.

“BostonGene’s AI platform stands out for its ability to synthesize clinical, molecular and imaging data–generating comprehensive, actionable insights that drive drug development and precision oncology,” said Steve Johansson, managing director, AI Breakthrough. “BostonGene’s AI platform delivers powerful, accurate and reproducible biological signatures that represent an enhanced approach drug development - bringing precision oncology closer to clinical reality.”

“Through our strategic collaborations with leading cancer centers and pharmaceutical companies, we are integrating advanced technology like AI into oncology care,” said Ferran Prat, PhD, JD, Chief Commercial Officer at BostonGene. “We’re grateful to AI Breakthrough for the ‘AI-based Drug Discovery Solution of the Year’ award, and we will continue to focus on using innovative AI-powered solutions to revolutionize personalized cancer treatment, expedite drug development and improve patient outcomes.”

The AI Breakthrough Awards shine a spotlight on the boldest innovators and most impactful technologies that are leading the charge in AI across a comprehensive set of categories, including Generative AI, Computer Vision, AIOps, Agentic AI, Robotics, Natural Language Processing, industry-specific AI applications and many more. This year’s program attracted more than 5,000 nominations from over 20 different countries, underscoring the explosive growth and global importance of AI as a defining technology of the 21st century.

About BostonGene Corporation

BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit www.BostonGene.com.

About AI Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the AI Breakthrough Awards program is devoted to honoring excellence in Artificial Intelligence technologies, services, companies and products. The AI Breakthrough Awards provide public recognition for the achievements of AI companies and products in categories including Generative AI, Machine Learning, AI Platforms, Robotics, Business Intelligence, AI Hardware, Computer Vision and more. For more information visit AIBreakthroughAwards.com.

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

“BostonGene’s AI platform delivers powerful, accurate and reproducible biological signatures that represent an enhanced approach drug development - bringing precision oncology closer to clinical reality.”

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.